{
  "id": "5ca0bf00ecadf2e73f000045",
  "type": "factoid",
  "question": "Reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?",
  "ideal_answer": "Reslizumab in the treatment of severe eosinophilic asthma:\u00a0an update.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29554826",
    "http://www.ncbi.nlm.nih.gov/pubmed/27445482",
    "http://www.ncbi.nlm.nih.gov/pubmed/28344579",
    "http://www.ncbi.nlm.nih.gov/pubmed/27458609",
    "http://www.ncbi.nlm.nih.gov/pubmed/29059618",
    "http://www.ncbi.nlm.nih.gov/pubmed/28683596",
    "http://www.ncbi.nlm.nih.gov/pubmed/30346831",
    "http://www.ncbi.nlm.nih.gov/pubmed/29486600",
    "http://www.ncbi.nlm.nih.gov/pubmed/28421429",
    "http://www.ncbi.nlm.nih.gov/pubmed/23326187"
  ],
  "snippets": [
    {
      "text": "Since IL-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting IL-5/IL-5R\u03b1 have been developed and/or marketed, including Mepolizumab, Reslizumab, and Benralizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reslizumab, a humanized mAb against IL-5, reduces the number of eosinophils in the blood and lungs. Based on efficacy and safety data from pivotal RCTs, reslizumab had been approved for use as an add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults who have a history of exacerbations despite receiving their current asthma medicines. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29486600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reslizumab in the treatment of severe eosinophilic asthma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29554826",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Reslizumab is a humanized monoclonal (immunoglobulin G4/\u03ba) antibody that binds with high affinity to circulating human IL-5 and downregulates the IL-5 signaling pathway, potentially disrupting the maturation and survival of eosinophils.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reslizumab (Cinqaero\u00ae; Cinqair\u00ae) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28421429",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nReslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30346831",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In particular, reslizumab is a humanized anti-IL-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27445482",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reslizumab (Cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the BREATH phase III clinical trial programme.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28421429",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reslizumab in Eosinophilic Asthma: A Review.Reslizumab (Cinqaero<sup>\u00ae</sup>; Cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28421429",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Reslizumab is a humanized monoclonal (immunoglobulin G4/\u03ba) antibody that binds with high affinity to circulating human IL-5 and downregulates the IL-5 signaling pathway, potentially disrupting the maturation and survival of eosinophils. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reslizumab (Cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27458609",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "eosinophilic asthma"
}